Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

85 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
Delgado J, Pean E, Melchiorri D, Migali C, Josephson F, Enzmann H, Pignatti F. Delgado J, et al. Among authors: melchiorri d. ESMO Open. 2021 Apr;6(2):100087. doi: 10.1016/j.esmoop.2021.100087. Epub 2021 Mar 16. ESMO Open. 2021. PMID: 33735800 Free PMC article. Review.
Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects.
Moscetti L, Hennik P, Bolstad B, Camarero J, Josephson F, Melchiorri D, Sommerfelt Grønvold M, Sjoberg J, Botezatu M, Mulder J, Meulendijks D, Trullas Jimeno A, Zafiropoulos N, Bergh J, Enzmann H, Pignatti F. Moscetti L, et al. Among authors: melchiorri d. ESMO Open. 2020 Aug;5(4):e000856. doi: 10.1136/esmoopen-2020-000856. ESMO Open. 2020. PMID: 32847837 Free PMC article. Review.
Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
Ali S, Moreau A, Melchiorri D, Camarero J, Josephson F, Olimpier O, Bergh J, Karres D, Tzogani K, Gisselbrecht C, Pignatti F. Ali S, et al. Among authors: melchiorri d. Oncologist. 2020 Apr;25(4):e709-e715. doi: 10.1634/theoncologist.2019-0559. Epub 2019 Nov 14. Oncologist. 2020. PMID: 32297447 Free PMC article.
European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
Tzogani K, Florez B, Markey G, Caleno M, Olimpieri OM, Melchiorri D, Hovgaard DJ, Sarac SB, Penttilä K, Lapveteläinen T, Salmonson T, Bergh J, Gisselbrecht C, Pignatti F. Tzogani K, et al. Among authors: melchiorri d. ESMO Open. 2019 Sep 8;4(5):e000570. doi: 10.1136/esmoopen-2019-000570. eCollection 2019. ESMO Open. 2019. PMID: 31555488 Free PMC article. Review.
Optimising bench science to withstand regulatory scrutiny.
Borg JJ, Melchiorri D, Sepodes B, Caramella CM, Tomino C, Micallef B, Serracino-Inglott A, Nistico R. Borg JJ, et al. Among authors: melchiorri d. Pharmacol Res. 2019 Jan;139:491-493. doi: 10.1016/j.phrs.2018.10.014. Epub 2018 Oct 12. Pharmacol Res. 2019. PMID: 30321599 No abstract available.
85 results